Literature DB >> 10882637

Co-morbidity in Gaucher's disease results of a nationwide enquiry in Spain.

J Pérez-Calvo1, M Bernal, P Giraldo, M A Torralba, F Civeira, M Giralt, M Pocovi.   

Abstract

SHORT
INTRODUCTION: Gaucher's disease (GD) is an autosomal recessive disease produced by mutations of the Glucocerebrosidase gene. Carriers are considered to be healthy subjects because there is no manifestation of the disease, but they show signs of macrophage disfunction. The aim of the study was to determine if GD patients and non affected carriers risk suffering other diseases when compared to healthy non-carrier relatives.
DESIGN: Epidemiologic study of historic cohorts. The fact that they have one or two mutated alleles has been considered to be the risk factor leading to other conditions (Dementia, Parkinson disease, Ischemic stroke, Ischemic heart disease, Non rheumatic valvular disease, Cancer hematological and non-hematological, Pulmonary fibrosis, Tuberculosis, Gallstones and Schizophrenia). All people, patients, carriers and healthy controls shared the same genetical background and environmental influence. - Patients and relatives enrolled on the Spanish Gaucher Disease Registry were evaluated. STATISTICS: For the Relative-Risk calculation the Mantel-Haenszel test was applied. Yates' correction was used when size sample was too small. A value of p <0.05 was accepted for statistical significance.
RESULTS: 370 people, from 79 different families, were surveyed. We received evaluable information from 45 families (56%), totalling 258 people (69%): 59 healthy subjects (Mean age 32. 20, RANGE: 10-85; M 57.63%/F 42.37%), 132 carriers (Mean age 35.91, RANGE: 1-79; M 56.82%/F 43.18%) and 67 patients (Mean age 32.16, Range: 1-76; M 44.78%/F 55.22%. - Relative Risk of suffering any disease with regard to Gaucher's status: Patient vs Healthy 9.69 (95% Confidence interval [CI] 2.00-63.99; p 0.0006). Patient vs Carrier 3.74 (CI 1.53-9.27; p 0.001); Carrier vs Healthy 2.59 (CI 0. 52-12.50; p 0.21). Relative Risk of suffering any disease with regard to sex was 3.96 for female patients (CI 1.01-16.75; p 0.02) and 1.34 for female carriers (CI 0.27-6.75; p = 0.68).
CONCLUSION: As a group, Gaucher's patients seem to have a greater risk of suffering other common unrelated diseases than carriers or healthy relatives. This excess of risk is particularly higher among female patients and can not be explained in terms of differences in age. Carrier status doesn't seem to highten the risk of suffering other diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882637

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  5 in total

1.  A neurological symptom survey of patients with type I Gaucher disease.

Authors:  G M Pastores; N L Barnett; P Bathan; E H Kolodny
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 2.  'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

Authors:  M Biegstraaten; I N van Schaik; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.750

Review 3.  GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches.

Authors:  Giulietta M Riboldi; Alessio B Di Fonzo
Journal:  Cells       Date:  2019-04-19       Impact factor: 6.600

4.  A familial concurrence of schizophrenia and Gaucher's disease.

Authors:  Odysseas D Mouzas; Konstantinos E Siomos; Nikiforos V Angelopoulos
Journal:  Ann Gen Psychiatry       Date:  2007-12-17       Impact factor: 3.455

5.  Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease.

Authors:  Derralynn Hughes; Maria Domenica Cappellini; Marc Berger; Jan Van Droogenbroeck; Maaike de Fost; Dragana Janic; Theodore Marinakis; Hanna Rosenbaum; Jesús Villarubia; Elena Zhukovskaya; Carla Hollak
Journal:  Br J Haematol       Date:  2007-07-26       Impact factor: 6.998

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.